Affiliation:
1. UCLA Stein Eye Institute
Abstract
Abstract
Background
Recent observational case series have reported on the potential ototoxicity of teprotumumab. This study aims to objectively evaluate the incidence of teprotumumab induced ototoxicity in patients with TED, using the gold standard of baseline and post treatment audiometry.
Methods
In this prospective observational case series, consecutive patients who had been diagnosed with TED and were to receive teprotumumab had audiometry at: baseline, prior to each infusion and at 6 months follow up post treatment. An independent audiologist assessed the audiometry. Further, the incidence and natural history of otologic symptoms was also documented.
Results
52 patients were included (43 females, 9 males, mean (SD) age: 49 (13)). On objective testing (audiometry), only 63% patients had normal baseline audiometry. At 6 months follow up, of those with normal baseline audiometry, 1 / 32 (3%) had new onset hearing loss. Of those with abnormal baseline audiometry, 20% had mild hearing dysfunction at 6 months follow up. Overall, 5/52 (10%) of patients had objective hearing loss at 6 months. Following treatment, at 24 weeks, 29% reported subjectively new otologic symptoms. At 6 months, this reduced to 7.7%. A prior history of hearing loss was the main risk factor for hearing dysfunction following treatment with teprotumumab.
Conclusions
Long term hearing loss in TED patients with normal baseline hearing is rare following treatment with teprotumumab (incidence of 3%). Patients with baseline hearing dysfunction are at greater risk of hearing change and management of the dose and interval between infusions is recommended for this group.
Publisher
Research Square Platform LLC
Reference32 articles.
1. Teprotumumab for thyroid-associated ophthalmopathy;Smith TJ;N Engl J Med,2017
2. Teprotumumab for the treatment of active thyroid eye disease;Douglas RS;N Engl J Med,2020
3. Ugradar S. EVALUATION OF UNITED STATES THYROID EYE DISEASE PATIENTS RECEIVING AN ADDITIONAL COURSE OF TEPROTUMUMAB TREATMENT OVER TWO YEARS. In: American Thyroid Association. 2022.
4. Teprotumumab and Hearing Loss: Case Series and Proposal for Audiologic Monitoring;Belinsky I;Ophthal Plast Reconstr Surg,2022
5. Audiometric patterns in ototoxicity after radiotherapy and chemotherapy in patients of head and neck cancers;Malgonde MS;Indian J Palliat Care,2015